Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators...

Using 3 illustrative cases, Chaer et al discuss the options for the prevention and therapy of COVID-19 infection in patients with hematologic malignancies and...

Key Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...

Key Points. The development of second primary malignancy post-auto-HSCT for myeloma is associated with inferior progression-free and overall survival.Multiple...

Recent ASTCT guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and...

For patients with newly diagnosed multiple myeloma (MM) undergoing high dose chemotherapy-autologous stem cell transplant (HDT-ASCT), hematopoietic...

Chimeric antigen receptor (CAR) T cell (CAR-T) therapy represents a revolutionary treatment for patients with relapsed/refractory hematologic...

Opportunities for Early Career Investigators We are proud to announce a new CIBMTR Training and Leadership Program specifically for Early Career Investigators (ECI). As...

Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host...

Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory large B-cell lymphomaDurable responses...